Form 4: Lucid Diagnostics Grants 300,000 Restricted Shares to GC

Lucid Diagnostics Inc. granted 300,000 restricted common stock shares to General Counsel and Secretary Michael Adam Gordon, vesting in 2029.

Summary

• Michael Adam Gordon, General Counsel and Secretary of Lucid Diagnostics Inc., was granted 300,000 shares of common stock.
• The shares were granted on February 20, 2026, at a price of $0 per share.
• This grant represents restricted stock issued under the Issuer's 2018 Equity Plan.
• The restricted stock has a single vesting date of May 20, 2029.
• The shares are subject to forfeiture if the requisite service period is not completed.
• Following this transaction, Michael Adam Gordon beneficially owns a total of 1,000,000 shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and generally positive corporate governance action, as it aligns executive incentives with long-term shareholder value, though it does not directly impact immediate operational or financial performance.

Positives

• The grant of restricted stock aligns the interests of General Counsel Michael Adam Gordon with long-term shareholder value.
• The vesting schedule through May 20, 2029, acts as a retention mechanism for a key executive.
• The use of the 2018 Equity Plan indicates a structured approach to executive compensation.

Negatives

• The issuance of 300,000 restricted shares could lead to potential future dilution for existing shareholders upon vesting, although this is a common practice for executive compensation.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed, meaning the executive may not ultimately receive the shares.
• Future stock price performance could impact the value of the grant for the executive and the company's compensation expense.

Future Outlook

NA

Management Comments

• Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock, are a standard component of executive compensation packages across the biotechnology and medical diagnostics industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder value, a common practice for companies like Lucid Diagnostics Inc. as they develop and commercialize diagnostic tools.

Comparison to Industry Standards

• The grant of restricted stock to a General Counsel is a common practice in the biotech and healthcare sectors, comparable to compensation structures seen at companies like Exact Sciences (EXAS) or Guardant Health (GH) for their senior executives, where equity forms a significant portion of total compensation to encourage long-term commitment and performance.
• The vesting period until May 2029 is a relatively long-term horizon, which is typical for retention-focused equity awards in growth-oriented companies, aiming to secure executive talent through critical development and commercialization phases.

Corporate Governance

Related Party Transactions

• Grant of 300,000 restricted common stock shares to Michael Adam Gordon, General Counsel and Secretary, under the company's 2018 Equity Plan.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting, but also improved alignment of executive interests with long-term company performance.
• Employees: Standard executive compensation practices can set a precedent for other senior roles.
• Management: Michael Adam Gordon receives a significant equity award, incentivizing continued service and performance.

Next Steps

• Michael Adam Gordon must complete the requisite service period to avoid forfeiture of the restricted stock.
• The restricted stock will vest on May 20, 2029, assuming service conditions are met.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment stance. It primarily serves to disclose an insider's equity grant, which is a standard practice for executive retention and alignment.

Keywords

Lucid Diagnostics, LUCD, Form 4, restricted stock, equity grant, executive compensation, Michael Adam Gordon, General Counsel, SEC filing, insider transaction